LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Pfizer

Atidarymo kaina

SektoriusSveikatos priežiūra

22.82 1.06

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

22.45

Max

22.78

Pagrindiniai rodikliai

By Trading Economics

Pajamos

2.6B

3B

Pardavimai

-4B

14B

P/E

Sektoriaus vid.

16.732

56.602

Pelnas, tenkantis vienai akcijai

0.92

Dividendų pajamingumas

7.72

Pelno marža

21.633

Darbuotojai

81,000

EBITDA

2B

4.5B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+26.88% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

7.72%

2.45%

Kitas uždarbis

2025-07-29

Kitas dividendų mokėjimo data

2025-06-13

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-14B

131B

Ankstesnė atidarymo kaina

21.76

Ankstesnė uždarymo kaina

22.82

Naujienos nuotaikos

By Acuity

43%

57%

150 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Pfizer Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-01 18:41; UTC

Pagrindinės rinkos jėgos

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

2025-04-29 11:24; UTC

Uždarbis

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

2025-05-15 15:20; UTC

Svarbiausios naujienos

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

2025-05-12 22:14; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

2025-05-12 18:45; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

2025-05-12 17:14; UTC

Svarbiausios naujienos

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

2025-05-12 09:02; UTC

Karštos akcijos

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

2025-05-07 17:01; UTC

Svarbiausios naujienos

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

2025-05-07 09:30; UTC

Svarbiausios naujienos

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

2025-05-05 15:13; UTC

Rinkos pokalbiai
Uždarbis

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

2025-05-01 14:07; UTC

Uždarbis

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

2025-05-01 11:58; UTC

Uždarbis

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

2025-05-01 11:06; UTC

Uždarbis

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

2025-05-01 10:48; UTC

Uždarbis

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

2025-04-29 19:47; UTC

Uždarbis

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

2025-04-29 18:11; UTC

Uždarbis

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

2025-04-29 15:22; UTC

Uždarbis

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

2025-04-29 12:03; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

2025-04-29 11:46; UTC

Uždarbis

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

2025-04-29 11:42; UTC

Uždarbis

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

2025-04-29 11:12; UTC

Uždarbis

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

2025-04-29 10:52; UTC

Uždarbis

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

2025-04-29 10:51; UTC

Uždarbis

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

2025-04-29 10:50; UTC

Uždarbis

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

2025-04-29 10:47; UTC

Uždarbis

Pfizer: Expects to Continue to De-Lever in Prudent Manner

2025-04-29 10:47; UTC

Uždarbis

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

2025-04-29 10:46; UTC

Uždarbis

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

2025-04-29 10:45; UTC

Uždarbis

Pfizer: Reaffirmed Views Don't Currently Include Impact From Tariffs

2025-04-29 10:45; UTC

Uždarbis

Pfizer 1Q EPS 52c >PFE

2025-04-29 10:45; UTC

Uždarbis

Pfizer 1Q Adj EPS 92c >PFE

Akcijų palyginimas

Kainos pokytis

Pfizer Prognozė

Kainos tikslas

By TipRanks

26.88% į viršų

12 mėnesių prognozė

Vidutinis 27.94 USD  26.88%

Aukščiausias 32 USD

Žemiausias 24 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pfizer kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

18 ratings

5

Pirkti

13

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

22.855 / 23.85Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

150 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.